Literature DB >> 15734776

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.

K P Weinfurt1, Y Li, L D Castel, F Saad, J W Timbie, G A Glendenning, K A Schulman.   

Abstract

BACKGROUND: We examined the clinical relevance of skeletal-related events (SREs) for health state preferences, pain and health-related quality of life in patients with advanced prostate cancer and a history of bone metastases. PATIENTS AND METHODS: Data were from a clinical trial of zoledronic acid versus placebo in the treatment of SREs associated with advanced prostate cancer metastatic to bone. Patients (n=248) were included if they experienced an SRE during the study. Outcome measures were assessed at fixed intervals. We used mixed-effects models to estimate changes in outcomes after each patient's first SRE.
RESULTS: There were clinically meaningful and statistically significant declines in physical well-being after: radiation and pathologic fractures; functional well-being after radiation; and emotional well-being after radiation and pathologic fractures. There also were meaningful and significant declines in preference and utility scores after radiation and fracture. Pain intensity declined after radiation, but not after other SREs; no other pain measure changed substantively.
CONCLUSIONS: SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer. Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of SREs occur between scheduled outcome assessments. Implications for trial design are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15734776     DOI: 10.1093/annonc/mdi122

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  116 in total

1.  Guidelines for the management of castrate-resistant prostate cancer.

Authors:  Fred Saad; Sebastien J Hotte
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  SEOM guidelines for the treatment of bone metastases from solid tumours.

Authors:  Javier Cassinello Espinosa; Aránzazu González Del Alba Baamonde; Fernando Rivera Herrero; Esther Holgado Martín
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

3.  [Evaluation of biochemical bone metabolism parameters].

Authors:  A Hegele; P Olbert; H G Wahl; R Hofmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.

Authors:  Juan M Jimenez-Andrade; Aaron P Bloom; James I Stake; William G Mantyh; Reid N Taylor; Katie T Freeman; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

Review 5.  Prostate cancer in the elderly.

Authors:  Hatzimouratidis Konstantinos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

6.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

7.  Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.

Authors:  Kanramon Watthanasuntorn; Haisam Abid; Rosana Gnanajothy
Journal:  BMJ Case Rep       Date:  2018-12-13

8.  Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.

Authors:  Lawrence T Dauer; Matthew J Williamson; John Humm; Joseph O'Donoghue; Rashid Ghani; Robert Awadallah; Jorge Carrasquillo; Neeta Pandit-Taskar; Anne-Kirsti Aksnes; Colin Biggin; Vigdis Reinton; Michael Morris; Jean St Germain
Journal:  Health Phys       Date:  2014-04       Impact factor: 1.316

9.  The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

Authors:  J Jayasekera; E Onukwugha; K Bikov; C D Mullins; B Seal; A Hussain
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

10.  Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.

Authors:  Donald W Robinson; Ning Zhao; Fitzroy Dawkins; Ming Qi; Dennis Revicki
Journal:  Qual Life Res       Date:  2013-04-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.